Oruka Therapeutics Q2 net loss widens on higher R&D costs
ORKA•Cost drivers and other income
- R&D spending rose because of additional clinical trials, a licensing payment, and increased employee compensation.
- General and administrative expenses increased due to higher compensation and public company costs.
- Other income increased mainly from interest earned on higher cash and marketable securities.
Reported results and analyst coverage
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.55 |
| Q2 net loss | $41.21 million |
The current average analyst rating on the shares is "strong buy", with 14 "strong buy" or "buy" recommendations, no "hold" and no "sell" or "strong sell" ratings.
The average consensus recommendation for the biotechnology and medical research peer group is "buy." Wall Street's median 12-month price target for Oruka Therapeutics Inc is $150.00, about above its August 7 closing price of .
